Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
Remediation of the moldy environment needs to be considered
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al
10.1038/s41374-022-00737-3 77 XuS.WuB.ZhongB.LinL.DingY.JinX.et al (2021)
Wick, G
IL-1 is a typical inflammatory mediator produced by nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3 (NLRP3) inflammasome, leading to myocardial hypertrophy, heart failure, and coronary atherosclerosis [85, 86]
US$ 26.53
US$ 21.42
US$ 28.32
US$ 22.13
US$ 22.77
